Search results for "CEF"

showing 10 items of 318 documents

Comparative clinical trial of ceftazidime and imipenem/cilastatin in patients with severe nosocomial pneumonias and septicaemias.

1990

The efficacy and safety of ceftazidime and imipenem in patients with severe infections was compared in a randomized multi-centre trial. Patients on assisted respiration with clinical signs of pneumonia or septicaemia who had been in hospital for at least 3 days were studied. Twenty-one patients were treated with ceftazidime, 24 with imipenem. The mean duration of treatment was 9 days in both groups. At the end of the trial 17 patients (81%) of the ceftazidime group and 16 patients (67%) in the imipenem group were clinically cured or showed marked improvement. The bacteriological results showed an eradication of the causative pathogens in 17 of 21 cases in the ceftazidime group and 13 of 19 …

Microbiology (medical)Malemedicine.medical_specialtyImipenemCeftazidimeHospital-acquired pneumoniaCeftazidimeInternal medicineSepsismedicineHumansMulticenter Studies as TopicIn patientRandomized Controlled Trials as TopicCross Infectionbusiness.industryImipenem/cilastatinGermany WestGeneral MedicinePneumoniaMiddle Agedbacterial infections and mycosesmedicine.diseaseRespiration ArtificialSurgeryClinical trialPneumoniaDrug CombinationsImipenemInfectious DiseasesCilastatinFemalebusinessmedicine.drugThe Journal of hospital infection
researchProduct

Investigation of Spaceflight Induced Changes to Astronaut Microbiomes

2021

The International Space Station (ISS) is a uniquely enclosed environment that has been continuously occupied for the last two decades. Throughout its operation, protecting the health of the astronauts on-board has been a high priority. The human microbiome plays a significant role in maintaining human health, and disruptions in the microbiome have been linked to various diseases. To evaluate the effects of spaceflight on the human microbiome, body swabs and saliva samples were collected from four ISS astronauts on consecutive expeditions. Astronaut samples were analyzed using shotgun metagenomic sequencing and microarrays to characterize the microbial biodiversity before, during, and after …

Microbiology (medical)SalivaMicrobial diversityZoologymicrobiomeBiologySpaceflightMicrobiologylaw.inventionspaceflight03 medical and health sciencesAbundance (ecology)lawMicrobiomeastronautRelative species abundance030304 developmental biologyOriginal Research0303 health sciencesmetagenomicsinternational space station030306 microbiologyHuman microbiomeQR1-502MetagenomicsmicroarrayFrontiers in Microbiology
researchProduct

Multidrug and broad-spectrum cephalosporin resistance among Salmonella enterica serotype enteritidis clinical isolates in southern Italy.

2002

ABSTRACT From 1992 to 1997, only six sporadic isolates of Salmonella enterica serotype Enteritidis from patients with cases of gastroenteritis in southern Italy exhibited resistance to broad-spectrum cephalosporins. Five isolates produced SHV-12, and one isolate encoded a class C β-lactamase. The bla SHV-12 gene was located in at least two different self-transferable plasmids, one of which also carried a novel class 1 integron.

Microbiology (medical)Serotypemedicine.drug_classEpidemiologySalmonella enteritidisCephalosporinIntegronbeta-LactamasesMicrobiologyPlasmidDrug Resistance Multiple BacterialGenotypemedicineHumansamoxicillin plus clavulanic acid; ampicillin; antibiotic agent; aztreonam; beta lactamase; cefotaxime; cefoxitin; ceftazidime; cephalosporin derivative; chloramphenicol; kanamycin; plasmid DNA; streptomycin; sulfonamide; tobramycin antibiotic resistance; article; bacterial infection; bacterium isolate; DNA probe; gastroenteritis; gastrointestinal infection; Italy; nonhuman; nucleotide sequence; phenotype; plasmid; priority journal; Salmonella; Salmonella enterica Base Sequence; beta-Lactamases; Cephalosporin Resistance; Cross Infection; Drug Resistance Multiple Bacterial; Gastroenteritis; Genes Bacterial; Humans; Italy; Plasmids; Salmonella enteritidis; Salmonella Infections Bacteria (microorganisms); Negibacteria; Salmonella; Salmonella entericaCephalosporin ResistanceCross InfectionbiologyBase SequenceCephalosporin Resistancebiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationVirologyGastroenteritisItalySalmonella enteritidisSalmonella entericaGenes BacterialSalmonella Infectionsbiology.proteinPlasmidsJournal of clinical microbiology
researchProduct

Dissemination of CTX-M-Producing Escherichia coli in Freshwater Fishes From a French Watershed (Burgundy)

2019

International audience; The burden of extended-spectrum beta-lactamases producing Escherichia coli (ESBL-Ec), has increased over several decades. Freshwater ecosystems are suspected to play an important ecological and evolutionary role in driving the dissemination of antimicrobial resistance. The aim of our study was to decipher the occurrence of ESBL-Ec in a small watershed (Ouche river, Burgundy, France), targeting environmental matrices and fishes. Among cefotaxime resistant E. coli (ctxR Ec) isolates, we detected and characterized 36 ESBL-Ec from water, biofilm and fish guts. ctxR Ec and ESBL-Ec were found in samples from sites near the first small town, located downstream from the wate…

Microbiology (medical)Veterinary medicineCefotaximeESBL producing Escherichia coliantibiotic resistance[SDV]Life Sciences [q-bio]lcsh:QR1-502MLST E. colimedicine.disease_causeFreshwater ecosystemMicrobiologylcsh:Microbiologyclass 1 integron-integrase03 medical and health sciencesAntibiotic resistanceblaCTX–Mfreshwater;ESBL producing Escherichia coli;bla(CTX-M);class 1 integron-integrase;antibiotic resistance;fish;MLST E. colimedicine[SDV.BV]Life Sciences [q-bio]/Vegetal Biology14. Life underwaterbla(CTX-M)freshwaterEffluentEscherichia coliComputingMilieux_MISCELLANEOUS030304 developmental biologyOriginal Researchfish0303 health sciencesbiology030306 microbiologybiochemical phenomena metabolism and nutritionbiology.organism_classificationbacterial infections and mycoses6. Clean water13. Climate action[SDE]Environmental SciencesMultilocus sequence typingbla CTX–MOmnivoreBacteriamedicine.drugFrontiers in Microbiology
researchProduct

Optimal treatment of leptospirosis: queries and projections.

2006

Although the global burden of leptospirosis remains enormous and new aspects of the disease are constantly recognised, little progress has been achieved in the field of leptospirosis therapeutics and queries regarding the utility of antibiotics in the late severe form of the disease remain. From the currently existing data, conclusions on the efficacy of antibiotic administration in severe or late disease cannot easily be drawn, since clinical trials have different selection criteria and may focus on Leptospira serovars with different virulence. However, as a rule the benefit of the doubt should apply. Moreover, new options, such as ceftriaxone, have a superior safety profile to penicillin.…

Microbiology (medical)medicine.medical_specialtymedicine.drug_classAntibioticsDiseaseLeptospirosiMiceLeptospiramedicineAnimalsHumansPharmacology (medical)LeptospirosisIntensive care medicineAntibacterial agentLeptospirabiologybusiness.industryOptimal treatmentCeftriaxoneGeneral Medicinemedicine.diseasebiology.organism_classificationPenicillinLeptospirosisAnti-Bacterial AgentsClinical trialTreatmentSafety profileInfectious DiseasesDoxycyclineImmunologybusinessInternational journal of antimicrobial agents
researchProduct

Computational study on hydrolysis of cefotaxime in gas phase and in aqueous solution

2012

We are presenting a theoretical study of the hydrolysis of a β-lactam antibiotic in gas phase and in aqueous solution by means of hybrid quantum mechanics/molecular mechanics potentials. After exploring the potential energy surfaces at semiempirical and density functional theory (DFT) level, potentials of mean force have been computed for the reaction in solution with hybrid PM3/TIP3P calculations and corrections with the B3LYP and M06-2X functionals. Inclusion of the full molecule of the antibiotic, Cefotaxime, in the gas phase molecular model has been demonstrated to be crucial since its carboxylate group can activate a nucleophilic water molecule. Moreover, the flexibility of the substra…

Models MolecularReaction mechanismPopulationCefotaximebeta-Lactamaseschemistry.chemical_compoundComputational chemistryMoleculeCarboxylateeducationConformational isomerismReaction mechanismeducation.field_of_studyAqueous solutionHydrolysisWaterHydrogen BondingGeneral ChemistryAnti-Bacterial AgentsSolutionsKineticsMetallo-beta-lactamasesComputational MathematicsModels ChemicalchemistryIntramolecular forceMβLsQuantum TheoryThermodynamicsDensity functional theoryGasesJournal of Computational Chemistry
researchProduct

Izmaiņas elektroencefalogrammā un neirovizualizācijas metodēs pie ģeneralizētas krampju lēkmes

2017

Mērķis: Noskaidrot atšķirības interiktālā elektroencefalogrāfijā (EEG) pierakstītā smadzeņu pamatritmā, efektu no pielietotiem aktivācijas manevriem un izmaiņām neirovizualizācijā starp epilepsijas pacientiem ar ģeneralizētu krampju lēkmi anamnēzē bez epileptiskas aktivitātes interiktālā EEG(Grupa Nr.2) un ar epiletisku aktivitāti interiktālā EEG(Grupa Nr.1). Materiāli un metodes: Paula Stradiņa Klīniskās universitātes slimnīcas arhīvā tika atlasītas slimības vēstures pacientiem, kuri sirgst ar epilepsiju. Pacienti tika izvēlēti pēc pētījumā izvirzītajiem dalības kritērijiem. Tika izveidotas divas grupas, kuru dalībniekiem bija analizētas interiktālā EEG pieraksta pamatritma izmaiņas, aktiv…

Neirovizuālizācijas metodēsElektroencefalogrammāEpilepsijaĢeneralizēta krampju lēkmeFona aktivitāteMedicīna
researchProduct

Randomized Comparative Trial with Ceftizoxime and Cefotaxime in Urinary Tract Infections

1984

Ceftizoxime, a new, semisynthetic, beta-lactamase-resistant cephalosporin, is not metabolized in man and is excreted almost entirely as the original active compound in the urine. The efficacy and safety of ceftizoxime were assessed in 80 patients with acute and chronic urinary infections, with and without associated pathological conditions, in comparison with cefotaxime. Two dosage schedules, 1 g or 0.5 g every 12 h, i.v. or i.m. for 10 days, were adopted according to the severity of each case and to separate randomization tables for each schedule; causal agents were all sensitive to both drugs in vitro. The overall results were excellent. Safety was excellent in almost all cases. In this t…

NephrologyAdultMalemedicine.medical_specialtyCefotaximeRandomizationAdolescentmedicine.drug_classUrologyUrinary systemCephalosporin030232 urology & nephrologyCefotaximeUrineRandom Allocation03 medical and health sciences0302 clinical medicineInternal medicineCeftizoximemedicineHumansAgedClinical Trials as Topicbusiness.industryCeftizoximeDosing regimenBacterial InfectionsDrug ToleranceGeneral MedicineMiddle AgedComparative trialSurgeryNephrology030220 oncology & carcinogenesisUrinary Tract InfectionsFemaleSafetybusinessmedicine.drugUrologia Journal
researchProduct

Implications of irradiating the subventricular zone stem cell niche

2016

Radiation therapy is a standard treatment for brain tumor patients. However, it comes with side effects, such as neurological deficits. While likely multi-factorial, the effect may in part be associated with the impact of radiation on the neurogenic niches. In the adult mammalian brain, the neurogenic niches are localized in the subventricular zone (SVZ) of the lateral ventricles and the dentate gyrus of the hippocampus, where the neural stem cells (NSCs) reside. Several reports showed that radiation produces a drastic decrease in the proliferative capacity of these regions, which is related to functional decline. In particular, radiation to the SVZ led to a reduced long-term olfactory memo…

NeurogénesisNeoplasias encefálicasCarcinogenesisSubventricular zoneNeurogenesis:Diseases::Neoplasms::Neoplasms by Site::Nervous System Neoplasms::Central Nervous System Neoplasms::Brain Neoplasms [Medical Subject Headings]Brain tumorSubventricular zoneBrain damageBiologyBrain tumorsArticle03 medical and health sciencesLateral ventricles0302 clinical medicineRadioterapiaLateral VentriclesGliomamedicineAnimalsHumans:Diseases::Neoplasms::Neoplasms by Histologic Type::Neoplasms Nerve Tissue::Neuroectodermal Tumors::Neoplasms Neuroepithelial::Glioma [Medical Subject Headings]Stem Cell Nichelcsh:QH301-705.5:Anatomy::Cells::Stem Cells::Neural Stem Cells [Medical Subject Headings]Medicine(all)Neural stem cellsRadiationDentate gyrus:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Radiotherapy [Medical Subject Headings]NeurogenesisBrainCell BiologyGeneral MedicineAnatomymedicine.diseaseCélulas-madre neuralesNeural stem cellBrain tumormedicine.anatomical_structurelcsh:Biology (General)nervous system030220 oncology & carcinogenesis:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Disease-Free Survival [Medical Subject Headings]medicine.symptomNeuroscience030217 neurology & neurosurgeryDevelopmental BiologyStem Cell Research
researchProduct

Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapene…

2020

Background: Experience in real clinical practice with ceftazidime-avibactam for the treatment of serious infections due to gram&minus

Nosocomial pneumonia0301 basic medicineMicrobiology (medical)medicine.medical_specialtymedicine.drug_classmedicine.medical_treatment030106 microbiologyAntibioticscarbapenem-sparing regimenBiologymedicine.disease_causeBiochemistryMicrobiologyArticleCarbapenem-sparing regimen; Ceftazidime-avibactam; ESBL-producing Enterobacterales; Nosocomial pneumonia; Pseudomonas aeruginosa03 medical and health sciences0302 clinical medicineESBL-producing EnterobacteralesCarbapenem-sparing regimenInternal medicinemedicinePharmacology (medical)030212 general & internal medicineRenal replacement therapyGeneral Pharmacology Toxicology and PharmaceuticsRisk factorAdverse effectESBL-producing Enterobacterales; Pseudomonas aeruginosa; carbapenem-sparing regimen; ceftazidime-avibactam; nosocomial pneumoniaCeftazidime-avibactamPseudomonas aeruginosaceftazidime-avibactamnosocomial pneumonialcsh:RM1-950medicine.diseaseCeftazidime/avibactamPneumonialcsh:Therapeutics. PharmacologyInfectious DiseasesEndocrinologyBacteremiaPseudomonas aeruginosaESBL-producing Enterobacteralemedicine.drugAntibiotics
researchProduct